Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.

Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Explore the clinical features, complex burden, and underlying mechanisms of PN.
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.